interesting

An interesting article on US biotech companies - especially the passage saying that "The bigger wild card might come from M&A activity. Drug makers are pursuing big- and small-cap biotechs as a way of propping up their drug pipelines and bracing for the loss of patent protection on key products."

http://biz.yahoo.com/ibd/081104/feature.html?.v=1